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Abstract
Cancer antigen 15-3 (CA15-3) is considered as a marker for breast cancer recurrence. However, we encountered a
case where the patient showed postoperative elevation of the CA15-3 level due to pernicious anemia without
evidence of breast cancer recurrence. The patient was a 60-year-old postmenopausal woman. She had undergone
partial mastectomy and sentinel lymph node biopsy (SLNB) for her T1 left breast cancer. SLNB had indicated no
lymph node metastases. The tumor was positive for hormone receptors and negative for human epidermal growth
factor receptor 2. Therefore, an aromatase inhibitor and external beam irradiation had been administered as
adjuvant therapy. However, the CA15-3 level was found to be elevated at 6 months postoperatively. Although
imaging studies did not indicate breast cancer recurrence, CA15-3 levels continued to increase. Based on the
findings of blood tests and gastroendoscopy, a diagnosis of pernicious anemia due to vitamin B12 deficiency was
finally confirmed at 2 years and 6 months postoperatively. The CA15-3 level returned to normal after vitamin B12
administration. The possibility of pernicious anemia should be considered in cases of postoperative elevated CA15-3
levels with no evidence of recurrence in patients with early breast cancer.
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Background
Cancer antigen 15-3 (CA15-3) has been utilized as a
marker for breast cancer recurrence and therapeutic ef-
fect in patients with metastatic breast cancer. However,
elevated CA15-3 levels are also observed in other malig-
nancies and nonmalignant diseases, although less fre-
quently. Therefore, the differential diagnosis of CA15-3
level elevation in an early breast cancer patient with a
relapse-free postoperative course might be difficult. We
encountered a case where an early breast cancer patient
had an elevated CA15-3 level due to pernicious anemia
during the postoperative course.
Case presentation
A 60-year-old postmenopausal woman visited our hos-
pital for a routine 6-month follow-up after partial mast-
ectomy and sentinel lymph node biopsy (SLNB) for T1
left breast cancer. She had no subjective symptoms but
her CA15-3 level was found to be elevated. The patient
had diabetes mellitus, and the SLNB had indicated no
lymph node metastases. The histopathological findings
of the resected tumor were as follows: invasive ductal
carcinoma; tumor size, 10 × 8 mm; nuclear grade, 1; and
surgical margin, negative. pT1N0M0, stage I cancer was
diagnosed. The tumor was positive for estrogen receptor
and progesterone receptor, and negative for human epi-
dermal growth factor receptor 2 (HER2). The Ki-67
labeling index was 5 %. External beam irradiation
(50 Gy/25 Fr) and letrozole had been administered as
adjuvant therapy.
The CA15-3 level increased gradually to 40 U/ml
1 year postoperatively. Carcinoembryonic antigen was
maintained at a normal level. Computed tomography
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and bone scintigraphy were performed, but there was no
clinical evidence of breast cancer recurrence. At 2 years
and 6 months postoperatively, the CA15-3 level in-
creased to 80 U/ml and asymptomatic anemia was de-
tected. Therefore, the patient was referred to the
department of hematology and was hospitalized for fur-
ther examinations. Positron emission tomography-
computed tomography and bone marrow biopsy did not
show metastatic lesions. Further blood examinations in-
dicated pancytopenia, an elevated red blood cell mean
corpuscular volume (MCV), vitamin B12 deficiency, and
the presence of intrinsic factor and parietal cell anti-
bodies. Gastroendoscopy revealed chronic atrophic gas-
tritis. Finally, pernicious anemia was diagnosed. The
CA15-3 level returned to normal after vitamin B12 ad-
ministration (Fig. 1a, b). The patient is currently being
followed up at an outpatient clinic without recurrence of
breast cancer.
Discussion
CA15-3 is a tumor marker used to monitor patients with
certain cancers, especially breast cancer. MUC1, a cell
surface glycoprotein, is released into the serum where it
is referred to as CA15-3. MUC1 is expressed in both
mammary epithelial cells and mammary tumor cells, al-
though its expression on the latter is higher. Elevated
serum CA15-3 levels are a common feature in metastatic
breast cancer patients. CA15-3 has been recognized as a
more specific marker than carcinoembryonic antigen in
patients with breast cancer [1, 2]. CA15-3 level monitor-
ing is therefore useful in postoperative surveillance of
asymptomatic patients who have undergone surgery for
early breast cancer and in evaluation of the therapeutic
effect in metastatic breast cancer. CA15-3 elevation can
detect distant metastasis in approximately 70 % of
asymptomatic postoperative breast cancer patients [1].
However, an elevated CA15-3 level has been reported in
normal subjects (associated with aging, pregnancy, or
liver diseases) as well as in patients with other
malignancies (ovarian cancer, lung cancer, hepatocellular
cancer, colon cancer, prostatic cancer, pancreatic cancer,
chondroid syringoma, some hematological malignancies)
[3, 4]. Furthermore, there is no high-level evidence that
the early detection of recurrence based on an elevation
in tumor marker levels in early breast cancer patients
improves their prognosis [1]. Therefore, the American
Society of Clinical Oncology guideline reported that
there are no data supporting the use of CA15-3 for
monitoring patients for recurrence after primary breast
cancer therapy [5]. However, some organizations recom-
mend serial measurement of the CA15-3 level based on
its reported usefulness for the postoperative surveillance
of breast cancer patients by small studies [1]. Addition-
ally, noninvasive and economic postoperative monitoring
modalities for early breast cancer are in demand by both
patients and clinical oncologists [2]. CA15-3 levels have
been routinely measured at the discretion of attending
physicians in our hospital.
In the case reported here, the CA15-3 level was moni-
tored for postoperative surveillance. The patient was
considered to have a low risk for recurrence in the early
postoperative period based on the biological characteris-
tics of the tumor. Initially, a nonmalignant change such
as aging was considered to be the cause of CA15-3 ele-
vation, and hence, no immediate measures were taken
and the patient was followed up for 1 year. However, the
CA15-3 level continued to increase gradually, and pan-
cytopenia progressed in accordance. Therefore, carcin-
omatosis of the bone marrow was considered as a
potential cause of pancytopenia. Accordingly, the patient
was referred to the department of hematology and was
ultimately diagnosed with pernicious anemia due to a
vitamin B12 deficiency.
Pernicious anemia is caused by a vitamin B12 defi-
ciency, due to chronic atrophic gastritis in the presence
of autoantibodies against gastric parietal cells. Patients
with solid tumors such as gastric cancer, pancreatic can-
cer, and gastrointestinal neuroendocrine tumors are
Fig. 1 a Time course of the CA15-3 level. The CA15-3 level returned to normal after vitamin B12 (Vit. B12) administration. b Time course of the
white blood cell (WBC) count, hemoglobin (Hb) level, and platelet (Plt) count. Pancytopenia improved after vitamin B12 (Vit. B12) administration
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considered to have a high possibility of pernicious
anemia. However, pernicious anemia has not been re-
ported to occur at a high incidence in patients with
breast cancer [3]. Pernicious anemia can be managed
with monthly intramuscular vitamin B12 injections [6].
Triantafillidis et al. first reported an elevated CA15-3
level in patients with pernicious anemia [7] in 2002.
Thereafter, Symeonidis et al. reported an elevated CA15-
3 level in a large number of patients with pernicious
anemia [3]. However, no patients with breast cancer
were included in these reports. To our knowledge, this is
the first report of an elevated postoperative CA15-3 level
due to pernicious anemia in a patient with a history of
breast cancer and no evidence of recurrence.
MUC-1 is expressed in mammary epithelial as well as
tumor cells [3]. MUC-1 is also expressed in early eryth-
roid differentiation and is not expressed on mature
erythrocytes. Pernicious anemia is associated with eryth-
roid hyperplasia, which results in ineffective erythropoi-
esis. It has been hypothesized that MUC-1 is released
from megaloblastic erythroblasts undergoing apoptosis
in pernicious anemia patients [3]. This could explain the
elevated CA15-3 level in patients with pernicious
anemia.
In cases of an elevated serum CA15-3 level without
apparent breast cancer recurrence, pernicious anemia
due to vitamin B12 deficiency should be considered in
addition to other malignancies. However, since anemia
was not noted at 6 months postoperatively when the
CA15-3 increase was first noted, it was difficult to deter-
mine that pernicious anemia was the cause of CA15-3
elevation at that point. The apparent causal relationship
between breast cancer and pernicious anemia was not
established in this case.
Conclusions
In conclusion, the possibility of pernicious anemia
should be considered in cases of elevated postoperative
CA15-3 levels in patients with early breast cancer with-
out recurrence.
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